Literature DB >> 2983856

Nephroblastomatosis and Wilms' tumor. Clinical experience and management of seven patients.

R L Heideman, G M Haase, C L Foley, H L Wilson, W C Bailey.   

Abstract

Nephroblastomatosis is an uncommon abnormality believed to represent the persistence of embryonal renal tissue. Its association with simultaneous or eventual Wilms' tumor has led to the speculation that it is a premalignant lesion. The accumulated clinical experience with this process and its progression to Wilms' tumor in three of seven individuals is discussed. It is concluded that conservative tissue sparing surgery, chemotherapy, and ultrasonographic follow-up are the approaches most appropriate for the management of these difficult patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983856     DOI: 10.1002/1097-0142(19850401)55:7<1446::aid-cncr2820550704>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  An analysis of histology and DNA-ploidy in primary wilms tumors and their metastases and a study of the morphological effects of therapy.

Authors:  E H van Leeuwen; A Postma; J W Oosterhuis; A Meiring; C J Cornelisse; J Koudstaal; W M Molenaar
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  Blastemal cells of nephroblastomatosis complex share an onco-developmental antigen with embryonic kidney and Wilms' tumor. An immunohistochemical study on polysialic acid distribution.

Authors:  J Roth; I Blaha; D Bitter-Suermann; P U Heitz
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

3.  Nephroblastomatosis: the whole spectrum of abnormalities in one case.

Authors:  F Papadopoulou; S C Efremidis; N Gombakis; J Tsouris; T Kehagia
Journal:  Pediatr Radiol       Date:  1992

4.  Perlman and Wiedemann-Beckwith syndromes: two distinct conditions associated with Wilms' tumour.

Authors:  R G Grundy; J Pritchard; M Baraitser; A Risdon; M Robards
Journal:  Eur J Pediatr       Date:  1992-12       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.